IPWatchdog.com publishes guest contributions on a regular basis. We are also lucky to have a growing number of Featured Authors who themselves contribute on a regular basis. Below is our list of Featured Authors.
Gene Quinn is a US Patent Attorney and a principal lecturer of the most popular patent bar review course in the US. Gene’s particular specialty is in the area of patent law, litigation and strategic consulting. The majority of his practice is focused on software, computer implemented methods, business methods and Internet innovations. He also does work with electrical and mechanical inventions as well.
Gene is also the Editor and primary author of IPWatchdog. Gene founded IPWatchdog in October of 1999.
Gene is admitted to practice law in New Hampshire, is a Registered Patent Attorney licensed to practice before the United States Patent Office and is also admitted to practice before the United States Court of Appeals for the Federal Circuit.
Joe Allen served as a Professional Staffer on the U.S. Senate Judiciary Committee to former Senator Birch Bayh (D-IN). Allen played a key part in the successful passage of the landmark Bayh-Dole Act of 1980 and its subsequent amendments.
Allen was recruited in 1982 to serve as Executive Director of Intellectual Property Owners, Inc. (IPO), a trade association representing major research-intensive companies. Dormant at the time he arrived, the group was reactivated by Allen and soon doubled its membership and income. Most importantly of all, IPO achieved its most important objective – enactment of the Court of Appeals for the Federal Circuit. The creation of this court was a key feature in restoring lagging confidence in the value and worth of U.S. patents.
In 1992, Allen was asked to help restructure the National Technology Transfer Center (NTTC), created by Congress to support technology transfer between the federal laboratories and industry. Allen was elevated to President of the NTTC where he served for seven years.
Beth Hutchens is is an Intellectual Property attorney licensed to practice before the US Patent & Trademark Office and in the State of Arizona.
Beth is also a contributing author on IPWatchdog.com. She typically writes about Internet, trademark and/or copyright issues. She brings a unique perspective and flamboyant writing style to the subjects she writes about. Her mental sharpness and keen insight, along with a “take no prisoners” attitude, work to provide a fun, entertaining and always informative column.
Eric Guttag is a US Patent Attorney with over 30 years of corporate and private intellectual property law experience relating to patent, trademark, copyright, trade secret and unfair competition matters, computer and Internet law.
Eric is also a contributing author on IPWatchdog.com. Most frequently Eric writes about recent Federal Circuit cases, particularly those in the biotechnology, pharmaceutical and chemical areas.
Eric’s specialties including patent application drafting, prosecution, and patentability studies and patent and know-how licensing. His particular area of technical focus is in the chemical arts, although he also has experience with mechanical and optical inventions as well.
In 2012 Mr. Millien was recognized as one of the “World’s 300 Leading IP Strategists” by IAM Magazine.
A co-founder of PCT® Law Group, PLLC, which was established in 2008 with offices in Virginia, Florida, and Washington, DC, his practice includes developing strategies and counseling clients on patent, copyright, trademark, trade secret and entertainment matters, including negotiating and drafting patent applications and technology-related agreements.
Ed Silverman is a prize-winning journalist who has covered the pharmaceutical industry for the past 17 years. In addition to editing Pharmalot, he is currently an editor-at-large for Med Ad News.
Previously, he was a bureau chief for The Pink Sheet, the venerable industry newsletter, and a contributor to its sister publication, In Vivo magazine. Before that, Silverman worked as a business writer for The Star-Ledger of New Jersey, one of the nation’s largest daily newspapers, where he conceived and launched Pharmalot. During his 13-year tenure, he closely followed a variety of topics of concern to those who work for, and with, drug makers – drug development; mergers and acquisitions; regulatory oversight; safety and pricing controversies, and marketing issues.